Loading clinical trials...

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus | Clinical Trials | Clareo Health

UNKNOWNEARLY_PHASE1

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

NCT05930314•Peking Union Medical College Hospital

Summary

Investigator-initiated, single-arm, open-label, single dose clinical study to evaluate the safety and preliminary efficacy of CNCT19 in treatment of patients with refractory systemic lupus erythematosus(SLE) presented with active lupus nephritis or active immune thrombocytopenia.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\. Able to sign Informed Consent Form (ICF) ;
•2\. Males or females 18-70（include 18 and 70） years of age;
•3\. Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) 1997 or European League against Rheumatism(EULAR)/ the American College of Rheumatology (ACR) 2019 criteria .Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) 1997 or European League against Rheumatism(EULAR)/ the American College of Rheumatology (ACR) 2019 criteria .
•Group1:Have active, biopsy-proven proliferative lupus nephritis Class III or IV, or Class V using the 2003 ISN/RPS criteria. The biopsy must be performed in the 6 months prior to the screening visit or during the screening period. Have documentation of active renal disease defined as:24h Proteinuria\> 1.5 grams/day.
•Refractory lupus nephritis is defined as no induced remission to treatment regimens containing at least one immunosuppressant (including glucocorticoids, CTX, tacrolimus, MMF, and cyclosporine) after 3 to 6 months, accompanied by no reduction (or worsening) of proteinuria or persistent antibody positives.
•Group 2: Refractory thrombocytopenia: No response to treatment with at least 1 course of MP shock (1g for 3 days) or high dose of glucocorticoids (1mg/kgd equivalent dose of glucocorticoids) combined with 1 or more immunosuppressants. Before enrollment, at least 2 consecutive blood routine tests were performed to check platelets below 50×10\^9/L and above 30×10\^9/L. Other non-SLE causes of thrombocytopenia, such as infection, bone marrow suppression, and hypersplenism, were excluded.
•4\. Not pregnant or nursing.
•5\. Adequate organ functions indicated as: ALT and AST \< 3 times of the ULN； Total bilirubin \< 2mg/dL with the exception of patients with Gibert-Meulengracht syndrome, who may be included if their total bilirubin is \< 3 x ULN and direct bilirubin \< 1.5mg/dL ULN； An estimated glomerular filtration rate \< 30 mL/min/1.73 m\^2 at the screening visit Serum creatinine ≤1.5mg/dl(133umol/l); Must have a minimum level of pulmonary reserve, non-oxygenated blood oxygen saturation \>95%;
•6\. Lymphocyte count \> 0.4×10\^9/L；
•7\. Use a small dose of glucocorticoid (dose equivalent to ≤10mg/d prednisone) for not less than 1 month (except glucocorticoid intolerance).

Exclusion Criteria

•1\. Severe active central nervous system (CNS) lupus, including seizures, psychosis, cerebrovascular accidents;
•2\. Dialysis patients or creatinine clearance rate \< 30ml/min；
•3\. Pregnant or breast feeding；
•4\. Active infections (such as sepsis, bacteremia, fungemia, uncontrolled pulmonary infection, and active tuberculosis);
•5\. One of the following: HBsAg positive HCV-Ab positive HIV positive TP positive
•6\. Undergone major surgery assessed by the subjects as unsuitable for inclusion within 4 weeks prior to screening.
•7\. Had or is currently suffering from other malignant tumors within five years prior to screening, except for curable tumors with negligible risk of metastasis or death, such as cervical carcinoma in situ and skin basal cell carcinoma with adequate treatment;
•8\. The heart meets any of the following conditions: Left ventricular ejection fraction (LVEF) ≤45%; New York Heart Association (NYHA) Class III or IV congestive heart failure or active heart disease; Severe arrhythmias requiring treatment (except atrial fibrillation and paroxysmal supraventricular tachycardia); QTcB interval male ≥450ms, female ≥470ms (QTcB=QT/RR\^1/2); Had a myocardial infarction, bypass, or stent surgery within the 6 months prior to the study; Other heart diseases that the investigators judged unsuitable for inclusion;
•9\. Received live vaccine within 6 weeks prior to screening；
•10\. Participants who have participated in other interventional clinical studies within the 3 months prior to cell transfusion, received active investigational drug therapy, or who intend to participate in another clinical trial or receive treatment outside the protocol during the entire study period.
+4 more criteria

Locations (1)

Xiaofeng Zeng

Beijing, China

Key Dates

Start Date

June 19, 2023

Primary Completion Date

May 30, 2024

Completion Date

May 30, 2025

Last Updated

July 5, 2023

Enrollment

ESTIMATED participants

Conditions

Refractory Systemic Lupus ErythematosusLupus NephritisImmune Thrombocytopenia

Interventions

CNCT19 cell injection

DRUG

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277

Lupus Nephritis

View study

RECRUITINGPHASE2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983

Lupus Erythematosus, SystemicLupus Nephritis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 5, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Inclusion Criteria

Exclusion Criteria

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)